ライフサイエンスコーパス: thrombomodulin

1 antitrypsin) and endothelial injury (soluble thrombomodulin).

2 y receptors (endothelial protein C receptor, thrombomodulin).

3 selectin, intracellular adhesion molecule-1, thrombomodulin).

4 bin was enhanced 60-80-fold independently of thrombomodulin.

5 um von Willebrand factor and decreased serum thrombomodulin.

6 e anticoagulant protein C in the presence of thrombomodulin.

7 C in the absence or presence of the cofactor thrombomodulin.

8 posttranslational, O-linked glycosylation of thrombomodulin.

9 itope changes drastically in the presence of thrombomodulin.

10 C-terminal subdomain of EGF-like module 5 of thrombomodulin.

11 n the EPCR concentration is in excess of the thrombomodulin.

12 ntithrombin complex, IL-6, IL-8, and soluble thrombomodulin.

13 rotein C with the assistance of the cofactor thrombomodulin.

14 inal subdomain of EGF-like module 5 of human thrombomodulin.

15 ets include tissue plasminogen activator and thrombomodulin.

16 n by plasmin but not by thrombin or thrombin:thrombomodulin.

17 ipts included matrix metalloproteinase-1 and thrombomodulin.

18 face expression of endothelial anticoagulant thrombomodulin.

19 in sulfate glycosaminoglycan (GAG) domain on thrombomodulin.

20 oietin-2, von Willebrand Factor, and soluble thrombomodulin.

21 e and mice lacking the lectin-like domain of thrombomodulin.

22 tion was measured in the presence of soluble thrombomodulin.

23 ndothelial nitric oxide synthase (eNOS), and thrombomodulin.

24 es 1700-fold in the presence of the cofactor thrombomodulin.

25 KLF2, endothelial nitric oxide synthase, and thrombomodulin.

26 factor for aHUS in the form of mutations in thrombomodulin.

27 pression of the endothelial KLF2 target gene thrombomodulin.

28 05 (247-346) vs. 256 (224-294) p = 0.002 and thrombomodulin (7.1 [5.5-8.1] vs. 3.57 [3.03-4.71] p < 0

29 We investigated changes in the expression of thrombomodulin, a key component of the anticoagulant pro

30 Thrombomodulin, a transmembrane glycoprotein, exerts ant

31 e ability of mevastatin to increase eNOS and thrombomodulin accumulation in endothelial cells.

32 We propose that the mechanism of thrombomodulin action is to kinetically facilitate the p

33 ood hemostasis parameters, including soluble thrombomodulin, activated protein C, and disseminated in

34 issue factor (TF), and the importance of the thrombomodulin-activated protein C inhibitory pathway.

35 Furthermore, activation of the thrombomodulin-activated protein C pathway in the region

36 In an in vivo thrombin-infusion model of thrombomodulin activation in cynomolgus monkeys, previou

37 on is present and that natural anticoagulant/thrombomodulin activity is important after transplant.

38 An adenoviral construct expressing thrombomodulin (Adv/RSV-THM) was created and functionall

39 Thrombomodulin also accelerates the proteolytic activati

40 site providing a potential mechanism of how thrombomodulin alters thrombin substrate specificity.

41 is dependent on the complex of thrombin and thrombomodulin, an integral endothelial surface receptor

42 restingly, these effects are not specific of thrombomodulin and depend solely on binding to the fibri

43 tors required for both protein C activation (thrombomodulin and EPCR) and APC cellular signaling (EPC

44 and hemorrhage were associated with elevated thrombomodulin and ferritin levels.

45 Soluble thrombomodulin and its parent molecule appear to play a

46 High thrombomodulin and low protein C levels were significant

47 creasing BD was associated with high soluble thrombomodulin and low protein C levels.

48 that PF4 binds to GAG+ but not GAG- forms of thrombomodulin and native but not Gla-domainless protein

49 ), 2 were inconsistent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), a

50 transition requires the combined binding of thrombomodulin and protein C and restores activity of th

51 electively shifted to the active E form upon thrombomodulin and protein C binding.

52 Admission plasma thrombomodulin and protein C levels are predictive of cl

53 ch families, and the anticoagulant proteins, thrombomodulin and protein C.

54 is a significant interaction between soluble thrombomodulin and soluble intercellular adhesion molecu

55 Combinatorial analysis of soluble thrombomodulin and soluble intercellular adhesion molecu

56 he activated ECs and on the concentration of thrombomodulin and the degree of heparan-sulfate acceler

57 It is evident that thrombomodulin and the endothelial cell protein C recept

58 This study examined whether thrombomodulin and the endothelial cell protein C recept

59 n C in a reaction that requires the cofactor thrombomodulin and the endothelial protein C receptor.

60 city and high affinity to the GAG- domain of thrombomodulin and the Gla domain of protein C.

61 inverse relationship between plasma soluble thrombomodulin and the relative risk of coronary heart d

62 Concentrations of thrombomodulin and tissue factor were quantified by West

63 fold faster than wild-type in the absence of thrombomodulin and, over a slower time scale, spontaneou

64 ociated with amplification of E-selectin and thrombomodulin, and a reduction in protein C.

65 immunoreactivity for von Willebrand factor, thrombomodulin, and angiotensin-converting enzyme were c

66 ment 1.2 (PF1.2) and p-selectin, fibrinogen, thrombomodulin, and d-dimer.

67 uced levels of Kruppel-like factors 2 and 4, thrombomodulin, and eNOS mRNA, suggesting endothelial ce

68 anscription targets nitric oxide synthase 3, thrombomodulin, and monocyte chemoattractant protein-1.

69 s reflecting endothelial damage (syndecan-1, thrombomodulin, and sE-selectin) were measured and demog

70 ed interleukin-1alpha (IL-1alpha), IL-8, and thrombomodulin, and the protein expression of these gene

71 protein 1 (MMP-1), MMP-3, MMP-9, P-selectin, thrombomodulin, and vascular endothelial growth factor w

72 nine residues, including apolipoprotein A-I, thrombomodulin, and von Willebrand factor, may contribut

73 atory proteins (CD55, CD59, CD46, and CD141 [thrombomodulin]) and AP components in human glomerular m

74 was selectively impaired by 35% (P<0.05) and thrombomodulin anticoagulant activity was decreased by 2

75 Individuals with a high level of soluble thrombomodulin are associated with a significant reducti

76 tein where thrombin and the EGF456 domain of thrombomodulin are connected through a peptide linker.

77 both endothelial cell protein C receptor and thrombomodulin are down-regulated in coronary arteries w

78 ated activation of protein C by MzT bound to thrombomodulin are regulated by Na+-induced allosteric t

79 e are strongly coupled in the recognition of thrombomodulin, as seen for the interaction of human gro

80 Thrombomodulin-associated coagulopathy (TM-AC) is a newl

81 ulated endothelial nitric oxide synthase and thrombomodulin at mRNA and protein levels.

82 The epitope for thrombomodulin binding is shaped as a hot spot in exosit

83 smaller subset of the structural epitope for thrombomodulin binding recently documented by x-ray crys

84 e and proteinase-like, is affected by Na(+), thrombomodulin binding, or active site ligation.

85 changes occur in the active site loops upon thrombomodulin binding.

86 found unexpectedly to significantly increase thrombomodulin binding.

87 ad decreased expression of endothelium-bound thrombomodulin, but extremely elevated levels of soluble

88 Preincubation of thrombin with soluble thrombomodulin, but not heparin, inhibited the proteolys

89 ereas the K(m) for the thrombin- or thrombin:thrombomodulin-catalyzed reaction is 10-40-fold higher t

90 ding EGF-like domain 3 selectively abolished thrombomodulin cofactor activity for TAFI activation.

91 Thrombomodulin colocalization with these receptors on th

92 ugments protein C activation by the thrombin-thrombomodulin complex about 5-fold in vitro.

93 Although the thrombin/thrombomodulin complex activated all the mutants, carbox

94 menting protein C activation by the thrombin-thrombomodulin complex and in modulating the functions o

95 ein C to activated protein C by the thrombin.thrombomodulin complex by increasing its affinity for pr

96 ons may enhance the affinity of the thrombin.thrombomodulin complex for protein C and thereby promote

97 uirements: protein C binding to the thrombin-thrombomodulin complex requires EGF-like domain 4, where

98 adict amide exchange studies on the thrombin-thrombomodulin complex that suggested subtle changes occ

99 hibited protein C activation by the thrombin/thrombomodulin complex, it still increased the sensitivi

100 B (CPB), which is activated by the thrombin/thrombomodulin complex, plays a procoagulant role during

101 al and structural properties of the thrombin-thrombomodulin complex, prolongs the clotting time by ge

102 ugments protein C activation by the thrombin-thrombomodulin complex.

103 bin in the crystal structure of the thrombin-thrombomodulin complex.

104 ation of wild-type protein C by the thrombin-thrombomodulin complex.

105 surface area upon formation of the thrombin-thrombomodulin complex.

106 the activation of protein C by the thrombin-thrombomodulin complex.

107 n C and enhancing activation by the thrombin-thrombomodulin complex.

108 menting protein C activation by the thrombin-thrombomodulin complex.

109 cement in protein activation by the thrombin-thrombomodulin complex.

110 litates protein C activation by the thrombin-thrombomodulin complex.

111 otein C activation catalyzed by the thrombin-thrombomodulin complex.

112 ents activation of protein C by the thrombin-thrombomodulin complex.

113 , and nifedipine) abolished the reduction in thrombomodulin concentration observed after arterial flo

114 nonsurvivors had significantly greater mean thrombomodulin concentrations (10.6 +/- 2.2 ng/mL) than

115 onsurvivors of septic shock have circulating thrombomodulin concentrations 1.5 and 3 times greater th

116 Thrombomodulin concentrations after 90 minutes of venous

117 We speculate that measurement of plasma thrombomodulin concentrations in septic shock may be a u

118 liminated prothrombinase activity at soluble thrombomodulin concentrations of >/=1 nM.

119 Thrombomodulin concentrations were determined by an enzy

120 ltiple organ system failure have circulating thrombomodulin concentrations which are associated with

121 A thrombomodulin construct lacking EGF-like domain 3 funct

122 Thrombomodulin controls the complement arm of the innate

123 The thrombomodulin-deficient animals provide a murine model

124 We show that the abortion of thrombomodulin-deficient embryos is caused by tissue fac

125 Two mouse models (thrombomodulin-deficient TMPro mice and factor V Leiden

126 n 293 cells that coexpress EPCR variants and thrombomodulin demonstrate that protein C binding to EPC

127 VEGF-induced, thrombomodulin-dependent activation of protein C was dep

128 amily of molecules, accelerates the thrombin-thrombomodulin-dependent generation of activated protein

129 ve than thrombin or meizothrombin(desF1) for thrombomodulin-dependent protein C activation.

130 Blood samples were obtained for plasma thrombomodulin determinations every 6 hrs for 72 hrs in

131 work (factor IIa, factor V, factor VIII, and thrombomodulin), did not affect the existence of this re

132 oups, mice lacking the lectin-like domain of thrombomodulin displayed strongly attenuated systemic in

133 how that a single amino acid substitution in thrombomodulin dissociates the developmental function of

134 have used recombinant lectin-like domain of thrombomodulin domain 1 (TMD1) to demonstrate the action

135 r-beta antibody, which effectively prevented thrombomodulin downregulation during acute pressure over

136 In vitro co-culture studies revealed that thrombomodulin downregulation is caused by the paracrine

137 Provided that thrombomodulin EGF-like domain 3 was present, TAFI compe

138 For example, porcine thrombomodulin expressed on porcine aortic endothelial c

139 aused a 70% inhibition of atrial endocardial thrombomodulin expression and resulted in increased loca

140 However, thrombomodulin expression decreases in perturbed endothe

141 Decreased thrombomodulin expression may cause defective function o

142 Targeted restoration of atrial thrombomodulin expression with adenovirus-mediated gene

143 mice lacking the blood coagulation regulator thrombomodulin, fibrinolytic degradation products (FDP)

144 active site does not change the affinity of thrombomodulin fragments binding to exosite 1; however,

145 estigation demonstrated that ablation of the thrombomodulin gene in mice causes embryonic lethality b

146 that mutations in the promoter region of the thrombomodulin gene may constitute a risk for arterial t

147 is study was to analyze the 5' region of the thrombomodulin gene to determine whether mutations contr

148 nt intima-to-media ratio was observed in the thrombomodulin group relative to controls.

149 complement regulatory protein CD46 and human thrombomodulin (GTKO.hCD46.hTBM), that were transplanted

150 The lectin-like domain of thrombomodulin has anti-inflammatory properties.

151 and antifibrinolytic cofactor activities of thrombomodulin have distinct structural requirements: pr

152 tive fragment of its anticoagulant cofactor, thrombomodulin, have been determined by surface plasmon

153 spect to known interactions of thrombin with thrombomodulin, hirudin, rhodniin and heparin cofactor I

154 Transgenic expression of human thrombomodulin (hTBM), which has the potential to solve

155 ion of PAEC with the gene encoding for human thrombomodulin (hTM) resulted in expression of high leve

156 ion of activated protein C (aPC) by thrombin/thrombomodulin (IIa/TM) in the presence of PF4.

157 clusion of the endothelial markers ICAM1 and thrombomodulin in a logistic regression model resulted i

158 thrombin (within exosite I) also employed by thrombomodulin in its cofactor-enhanced activation of pr

159 in, but extremely elevated levels of soluble thrombomodulin in plasma, impairing the propagation phas

160 -alpha (TNF-alpha) on stable expressed human thrombomodulin in vitro.

161 nd decreased protein C activation because of thrombomodulin inactivation.

162 , the anti-inflammatory/anti-coagulant CD141/thrombomodulin increased markedly when IL-32 was silence

163 ion as a function of temperature reveal that thrombomodulin increases >1,000-fold the rate of diffusi

164 In competition experiments, thrombomodulin inhibited fibrin-enhanced factor XIII act

165 vironment around the scissile bond for II(a)/thrombomodulin interaction.

166 Thrombomodulin is a cofactor protein on vascular endothe

167 Endothelial thrombomodulin is a major vasoprotective molecule.

168 Thrombomodulin is a multidomain receptor primarily expre

169 Thrombomodulin is a necessary factor in the anticoagulan

170 The membrane thrombomodulin is digested by proteases and the degradat

171 ession of endothelial NO synthase (eNOS) and thrombomodulin is KLF2 dependent.

172 or the first time a detrimental role for the thrombomodulin lectin-like domain in the host response t

173 this study, we investigated the role of the thrombomodulin lectin-like domain in the host response t

174 Individuals with a high soluble thrombomodulin level do not have an increased risk of co

175 The soluble thrombomodulin level in plasma is an independent risk fa

176 Posttransplant thrombomodulin levels are elevated after transplant but

177 In contrast, at low soluble thrombomodulin levels, soluble intercellular adhesion mo

178 P<0.0001) but not of d-dimer, fibrinogen, or thrombomodulin levels.

179 t F1+2 and d-dimer), and endothelial damage (thrombomodulin) markers to near-normal levels.

180 Homozygous thrombomodulin-mutant ThbdPro mice, which have elevated

181 The same thrombomodulin mutation has been recently described in a

182 ity and thrombin generation in the demise of thrombomodulin-null embryos, and suggests that platelets

183 93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not.

184 The impact of local overexpression of thrombomodulin on in vivo thrombus formation was subsequ

185 is inhibitor (TAFI) is activated by thrombin/thrombomodulin on the endothelial cell surface, and func

186 The influence of protein C and soluble thrombomodulin on thrombin generation was correlated wit

187 PF4 had no measurable interaction with GAG- thrombomodulin or Gla-domainless protein C.

188 -Endothelial thrombomodulin plays a critical role in hemostasis by bi

189 ative feedback of the protein C pathway with thrombomodulin produced nonstationary patterns of wave f

190 endothelial cells, the increase in KLF2 and thrombomodulin protein by shRNA-induced decrease in p66s

191 of endothelial protein C receptor (EPCR) and thrombomodulin protein expressions, inhibited tissue tum

192 imes, prothrombin fragments 1+2, fibrinogen, thrombomodulin, protein C, plasminogen activator inhibit

193 Alterations in the thrombomodulin-protein C pathway are consistent with act

194 These findings show a new function for the thrombomodulin-protein C system in controlling the growt

195 03 regarding cationic proteins, PF4, and the thrombomodulin-protein C system was reviewed.

196 -kappaB activation and the impairment of the thrombomodulin-protein C-EPCR anticoagulation pathway.

197 that statin-dependent induction of eNOS and thrombomodulin requires KLF2 and thereby provides a nove

198 f circulating mitochondrial (mt)DNA, soluble thrombomodulin (sCD141) and ICAM-1, reflecting endotheli

199 llei, mice lacking the lectin-like domain of thrombomodulin showed a survival advantage, accompanied

200 We studied the effect of soluble thrombomodulin (sTM) in a hypoperfusion model of ischemi

201 ular adhesive molecule-1 (sICAM) and soluble thrombomodulin (sTM) levels are associated with risk of

202 ecule-1 (sVCAM-1), E-selectin (sE-Selectin), thrombomodulin (sTM), tissue factor (sTF) and vascular e

203 [eg, von Willebrand factor (vWf) and soluble thrombomodulin (sTM)]) and raised plasma levels of brain

204 conditions, there is rapid downregulation of thrombomodulin, sufficient to limit protein C activation

205 (histone-complexed DNA fragments, annexin V, thrombomodulin, syndecan-1), platelet activation (solubl

206 lower expression of ICAM1, ICAM2, VCAM1, and thrombomodulin than do HUVEC and HMVEC.

207 l malfunction associated with the absence of thrombomodulin than fibrin formation.

208 ibe structures on recombinant membrane-bound thrombomodulin that are required for human TAFI activati

209 Solulin is a soluble form of thrombomodulin that is resistant to proteolysis and oxid

210 537Stop), which predicts a truncated form of thrombomodulin that is shed from the vascular endotheliu

211 some 20 (and putatively on the THBD gene for thrombomodulin) that increased the risk of venous thromb

212 Absence of the blood coagulation inhibitor thrombomodulin (Thbd) from trophoblast cells of the mous

213 gote minor allele of a common variant in the thrombomodulin (THBD) gene (rs1042579) was independently

214 ene encoding the blood coagulation inhibitor thrombomodulin (Thbd) leads to embryonic lethality cause

215 ial cell stress is involved, and endothelial thrombomodulin (THBD) plays a role in this process.

216 that SNPs on chromosome 20 are cis-eQTLs for thrombomodulin (THBD), and the expression of THBD is low

217 Here we identify the thrombomodulin (Thbd)-activated protein C (aPC) pathway

218 ng were also induced, including plasminogen, thrombomodulin, the urokinase-type plasminogen activator

219 hat cationic PF4 binds to both protein C and thrombomodulin through these anionic domains.

220 Thrombomodulin thus represents a central mechanism by wh

221 Overexpression of KLF2 strongly induced thrombomodulin (TM) and endothelial nitric oxide synthas

222 use PECAM-1 antibodies to recombinant murine thrombomodulin (TM) and endothelial protein C receptor (

223 f the anticoagulant and protective receptors thrombomodulin (TM) and endothelial protein C receptor (

224 ned radiation-induced changes in endothelial thrombomodulin (TM) and protease-activated receptor-1 (P

225 Now we isolate human EPCR and thrombomodulin (TM) and reconstitute them into phosphati

226 he expression of the anticoagulant proteins, thrombomodulin (TM) and the endothelial cell protein C r

227 nsion leads to PDGFR activation and identify thrombomodulin (TM) as an Akt and AP-1 target in SMC.

228 ess the endothelial-specific genes tie-2 and thrombomodulin (TM) as well as the early mesodermal mark

229 Statins upregulate endothelial thrombomodulin (TM) by mechanisms that involve members o

230 Endothelial thrombomodulin (TM) changes thrombin's substrate specifi

231 en to make the fibrin clot, but the thrombin-thrombomodulin (TM) complex initiates the anticoagulant

232 ctivated protein C (APC) by soluble thrombin/thrombomodulin (TM) complexes up to 25-fold.

233 Thrombomodulin (TM) forms a 1:1 complex with thrombin.

234 Thrombomodulin (TM) functions as a cofactor to enhance t

235 onsecutively inactivated both alleles of the thrombomodulin (TM) gene in murine embryonic stem (ES) c

236 Sporadic mutations in the thrombomodulin (TM) gene occur in patients with both art

237 order in which a p.Cys537Stop variant in the thrombomodulin (TM) gene THBD, results in high plasma TM

238 The thrombomodulin (TM) gene was ablated in mice in a cell t

239 is study used mice with modifications of the thrombomodulin (TM) gene, the tissue-type plasminogen ac

240 The endothelial cell surface receptor thrombomodulin (TM) inhibits blood coagulation by formin

241 Thrombomodulin (TM) is a cofactor for protein C activati

242 Thrombomodulin (TM) is a cofactor for thrombin-mediated

243 Thrombomodulin (TM) is a predominantly endothelial trans

244 The interaction of thrombin (IIa) with thrombomodulin (TM) is essential for the efficient activ

245 Thrombomodulin (TM) is expressed on the endothelial surf

246 The cofactors heparin, vitronectin (VN), and thrombomodulin (TM) modulate the reactivity of alpha-thr

247 In this study, we describe a novel thrombomodulin (TM) mutation (c.1611C>A) that codes for

248 rporating the catalytically active domain of thrombomodulin (TM) onto the micelle corona for the loca

249 Endothelial thrombomodulin (TM) regulates coagulation and inflammati

250 Thrombin undergoes allosteric modulation by thrombomodulin (TM) that results in a shift in macromole

251 f the ability of chondroitin sulfate (CS) on thrombomodulin (TM) to enhance affinity for TM and to el

252 The binding of thrombomodulin (TM) to exosite-1 and the binding of Na(+

253 e influence of the protein C system, soluble thrombomodulin (Tm) was also added to the reaction mixtu

254 mutants of residues in the fourth domain of thrombomodulin (TM) were prepared and assayed for protei

255 Thrombomodulin (TM), a central player of the anticoagula

256 Endothelial cell expression of thrombomodulin (TM), a key component of the anticoagulan

257 Thrombomodulin (TM), a key component of the anticoagulan

258 Thrombomodulin (TM), a type I transmembrane glycoprotein

259 Based on evidence that abnormalities in thrombomodulin (TM), an anticoagulant endothelial glycop

260 Thrombomodulin (TM), an endothelial cell membrane recept

261 ified endothelial protein C receptor (EPCR), thrombomodulin (TM), and von Willebrand factor (VWF) by

262 n C activation by thrombin in the absence of thrombomodulin (TM), but the metal ion is required for a

263 d that LPS binds to monocytic membrane-bound thrombomodulin (TM), but the role of monocytic TM in LPS

264 ing the fourth and fifth EGF-like domains of thrombomodulin (TM), is deleterious for TM activity.

265 Thrombomodulin (TM), or its epidermal growth factor-like

266 mediating the interactions of thrombin with thrombomodulin (TM), protein C, and thrombin-activatable

267 With thrombin in the absence of thrombomodulin (TM), these polysaccharides markedly redu

268 f intercellular adhesion molecule 1 (ICAM1), thrombomodulin (TM), tissue factor (TF) and tissue facto

269 f plasminogen activator inhibitor-1 (PAI-1), thrombomodulin (TM), tissue plasminogen activator (tPA),

270 s pathway is the cytokine-regulated receptor thrombomodulin (TM), which functions as a co-factor for

271 l cells (PAEC) does not provide the expected thrombomodulin (TM)-cofactor activity for human protein

272 oagulant substrates while largely preserving thrombomodulin (TM)-dependent protein C activation.

273 ovascular injury is established, the role of thrombomodulin (TM)-dependent protein C antithrombotic m

274 l other residues are poised to interact with thrombomodulin (TM).

275 dothelial cell adhesion molecule (PECAM) and thrombomodulin (TM).

276 activation, is augmented about 1250-fold by thrombomodulin (TM).

277 and of the recombinant lectin-like domain of thrombomodulin (TM).

278 thrombin bound to an 83-aa fragment of human thrombomodulin [TMEGF(4-5)].

279 interface between thrombin and a fragment of thrombomodulin, TMEGF45, have been monitored by amide hy

280 h EGF-like domain (residues Q387 to E426) of thrombomodulin (TMEGF5) has been determined by two-dimen

281 Targeting thrombomodulin to circulating red blood cells augments i

282 215-217 beta-strand, and whether binding of thrombomodulin to exosite I can allosterically shift the

283 ing of a fragment of the regulatory protein, thrombomodulin, to exosite 1 on the back side of the thr

284 Human thrombomodulin transgenic PAECs are less sensitive to ac

285 ly, these functions do not require exogenous thrombomodulin, unlike other anticoagulant thrombin deri

286 34, endothelial cell protein C receptor, and thrombomodulin using a streptavidin-biotin-peroxidase me

287 Mean thrombomodulin values increased as the number of organ s

288 pendent predictor of <24-hours mortality and thrombomodulin was an independent predictor of 7-day and

289 The significant reduction in thrombomodulin was attenuated if calcium was removed fro

290 ch EPCR was expressed at moderate levels and thrombomodulin was low.

291 e functional epitope of thrombin recognizing thrombomodulin was mapped using Ala-scanning mutagenesis

292 ator inhibitor were significantly higher and thrombomodulin was significantly lower in Fabry patients

293 EPCR and thrombomodulin were both expressed on the endothelium of

294 ntercellular adhesion molecule 1 (ICAM1) and thrombomodulin were measured in a subgroup.

295 luding endothelial nitric-oxide synthase and thrombomodulin, whereas knockdown of Kruppellike factor

296 (KD = 4 nM) and shows that PF4 binds to GAG+ thrombomodulin with a KD of 31 nM and to protein C with

297 e but activates protein C in the presence of thrombomodulin with a specificity comparable with wild-t

298 mation regarding the relationship of soluble thrombomodulin with coronary heart disease.

299 thrombin with the endothelial cell receptor thrombomodulin with subsequent generation of activated p

300 intercellular gaps, and loss of ATDPase and thrombomodulin, with release of heparan sulfate.